SULFAMONOMETHOXINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H12N4O3S
Molecular Weight	280.303
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1

InChI

InChIKey=WMPXPUYPYQKQCX-UHFFFAOYSA-N

InChI=1S/C11H12N4O3S/c1-18-11-6-10(13-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,14,15)

HIDE SMILES / InChI

Description
Sources: http://www.rusmedserv.com/lekarstva/komponent/sulfamonomethoxine.html
Curator's Comment: description was created based on several sources, including https://www.goldbio.com/product/3383/sulfamonomethoxine http://ft.chqmarket.com/en/1059-compound-sulfamonomethoxine-sodium-injection-baclean.html

Sulfamonomethoxine is a long-acting sulfonamide antibiotic. It is active against Streptococcus spp. (Including Streptococcus pneumoniae, Enterococcus spp.), Staphylococcus spp., Escherichia coli, Shigella spp., some strains of Proteus spp., Neisseria gonorrhoeae, Neisseria meningitides. Sulfamonomethoxine also active against Chlamydia spp., Toxoplasma gondii, Plasmodium. Rapidly absorbed from the gastrointestinal tract, it penetrates the BBB. The relatively low toxicity. Sulfamonomethoxine is a competitive inhibitor of dihydropteroate synthetase used to block the synthesis of folic acid. By preventing the production of folate in bacteria, the sulfonamide antibiotics ultimately suppress bacterial DNA replication.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
batcerial dihydropteroate synthetase 4 Target ID: batcerial dihydropteroate synthetase Sources: http://www.rusmedserv.com/lekarstva/komponent/sulfamonomethoxine.html	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial Infections 63 Sources: http://www.rusmedserv.com/lekarstva/komponent/sulfamonomethoxine.html	Curative		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.	1995 Aug	7486915
In-vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species.	2007	17287722

Patents

Sample Use Guides

In Vivo Use Guide

adult: 1 tablet per day (500 mg- 1 g per day) children: 25 mg/kg per day at the first day, then 12,5 mg/kg per day

Route of Administration: Oral

In Vitro Use Guide

It was shown that 9 strains of P. mallei were sensitive to sulfanilamides and their combinations with trimethoprim: sulfamonomethoxine + trimethoprim (2.5:1), etc. The activity of the sulfamonomethoxine combination with trimethoprim (sulfate) was lower.

Name

Type

Language

SULFAMONOMETHOXINE

Official Name

English

SULFAMONOMETHOXINE [MART.]

Common Name

English

NSC-757862

Code

English

SULFAMONOMETHOXINE [JAN]

Common Name

English

DAIMETON

Brand Name

English

sulfamonomethoxine [INN]

Common Name

English

SULFAMONOMETHOXINE [USAN]

Common Name

English

Sulfamonomethoxine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01EQ18